

# Breakout session on pragmatic trials – a HTA perspective

**Beate Wieseler** 


ACT EU PA08 multi-stakeholder workshop on methodology guidance: collaborating across the regulatory network

23 November 2023



#### Context of health technology assessment

- Our question: comparative effectiveness (is there any difference between a new intervention and the current standard of care/best available treatment?)
- => inform treatment decisions, inform pricing and reimbursement decisions



- We often lack data to answer our question (on comparative effects, on patients we are treating in routine care, on endpoints that are relevant)
- We need more and other studies to enable a description of comparative effectiveness




#### Why pragmatic trials?

- We need more (randomised) comparative trials
- We need data on comparative effects in patients we are treating in routine care
  - (limited narrow populations not covering patients treated in routine practice are not a consequence of randomisation but of decisions on inclusion criteria)
  - Caveat for broad populations: in case of heterogenous populations, assessment of effect modification by patient characteristics required
- We need faster and less expensive trials => randomised registry-based pragmatic trials

## R-RCT vs. RCT STEMI Thrombectomy Story (SWEDEHEART-Register)





1st patient: June 2010

30 centers

33 months to full enrollment

7,244 patients

1st patient: August 2010

87 centers

48 months to full enrollment

10,732 patients







### Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)



Im Mediapark 8 50670 Köln

Telefon +49 221 35685-0 Telefax +49 221 35685-1

info@iqwig.de

www.iqwig.de www.gesundheitsinformation.de www.themencheck-medizin.de



@iqwig@wisskomm.social @iqwig\_gi@wisskomm.social